{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72","upperLimit":"95","value":"88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Time elapsed between Day 0 and death from any cause, whichever came first, assessed up to 3 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine 225 mg/m\\^2 total, Melphalan 200 mg/m\\^2 total (140 mg/m\\^2 total for patients with Creatinine Clearance \\<70 ml/min)","id":"OG000","title":"Phase 2"}],"paramType":"MEDIAN","populationDescription":"Phase 2 includes all patients treated on phase 2 of the study (28 patients), and patients treated at Dose Level 6 of the Phase 1 portion of the study (7 patients). The dose level used during Phase 2 was Dose Level 6.","reportingStatus":"POSTED","timeFrame":"From Day 0 until time of death, assessed up to 3 years.","title":"Overall Survival at 3 Years (Phase 2)","type":"SECONDARY","unitOfMeasure":"Percentage of participants alive"}